Truist Securities Maintains Buy on CG Oncology, Raises Price Target to $85
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsPrice Target
Truist Securities analyst Gregory Renza maintains CG Oncology (NASDAQ:CGON) with a Buy and raises the price target from $82 to $85.
Truist Securities analyst Gregory Renza maintains CG Oncology (NASDAQ:CGON) with a Buy and raises the price target from $82 to $85.